# Marty Makary **FDA Commissioner** (confirmed March 2025; reported to be fired as of May 8, 2026) and Johns Hopkins surgical oncologist who became the Trump administration's instrument for translating the [[MAHA]] agenda into regulatory action at the FDA. Makary is the figure who illustrates the tension at the heart of MAHA: a credentialed mainstream physician who lent institutional legitimacy to a health-skeptic political movement — and who is now apparently being discarded by the same administration that appointed him, not for going too far but for not going far enough on vapes and the abortion pill. ## Background ### Education and Medical Career Makary's credentials are not in question. He is a genuinely accomplished physician-researcher: - **BA** from Bucknell University - **MD** from [[Thomas Jefferson]] University - **MPH** from Harvard T.H. Chan School of Public Health - **Surgical residency** at Georgetown University; sub-specialty training at Johns Hopkins - **Mark Ravitch Chair in Gastrointestinal Surgery** at Johns Hopkins School of Medicine - **Chief of Islet Transplant Surgery** at Johns Hopkins - Credentials Chair, Director of Quality and Safety for Surgery, and multiple other leadership roles at Johns Hopkins He is the author of four books: *Unaccountable* (2012, on medical errors and transparency), *The Price We Pay* (2019, on healthcare pricing and billing), *Mama Maggie* (a profile of a humanitarian), and *Blind Spots* (on medical groupthink). *The Price We Pay* received bipartisan praise for its exposure of hospital pricing opacity and surprise billing — issues where Makary's analysis was mainstream and well-regarded. ### The COVID Pivot Makary's trajectory from mainstream physician to MAHA-adjacent figure tracks through the pandemic: **Early 2020:** Called for taking COVID seriously; supported national lockdown to slow the spread. **May 2020:** Advocated universal masking to enable businesses and schools to reopen. **2020–2021:** Increasingly critical of prolonged lockdowns, school closures, and broad vaccine mandates for younger populations. Supported vaccines for adults but opposed mandates and boosters for younger, healthy people. Became a regular voice in the "lockdown skeptic" lane — not anti-vax but anti-mandate, anti-prolonged-closure, and increasingly critical of the public health establishment's communication failures. **February 2021:** Published a Wall Street Journal op-ed predicting COVID would be "mostly gone by April" 2021 due to natural immunity — a prediction that aged badly when Delta and Omicron variants killed hundreds of thousands more Americans. **2021–2024:** Regular contributor to conservative media and the [[American Enterprise Institute]] (a fellow). Positioned himself as a "heterodox" medical voice challenging public health orthodoxy — a brand that made him attractive to the MAHA coalition. The COVID arc is important because it illustrates a pattern: Makary's individual critiques were often defensible in isolation (school closures were too long, mandates for young healthy people were debatable, public health messaging was poor). But the *aggregated effect* of his commentary — amplified through conservative media and AEI — contributed to a broader delegitimization of public health institutions that the MAHA movement then exploited. ### AEI Connection Makary's fellowship at the [[American Enterprise Institute]] places him in the right-wing think tank infrastructure documented throughout this KB. AEI provided the institutional platform for his COVID-era commentary and connected him to the policy networks that produced the Trump nomination. ## FDA Commissioner Tenure (March 2025 – May 2026) ### Nomination and Confirmation Trump announced Makary as his FDA commissioner nominee in November 2024. The Senate confirmed him in March 2025 — with bipartisan support, reflecting his mainstream credentials and the fact that he was seen as a "reasonable" pick relative to the MAHA movement's more extreme figures. ### Key Actions **COVID vaccine restrictions (May 2025).** Makary and then-FDA vaccine chief **Dr. Vinay Prasad** announced that the FDA would no longer routinely approve COVID-19 shots for healthy adults under 65 or children without underlying health conditions. The announcement was made through a medical journal article — bypassing the FDA's traditional outside advisory committees, which Makary called a "kangaroo court." The decision left hundreds of millions still eligible but sent a signal about the administration's vaccine posture. **Food dye phase-out.** Working with [[RFK Jr.]]'s HHS, the FDA announced plans for food manufacturers to voluntarily phase out several petroleum-based artificial food dyes by 2027, citing concerns about links to ADHD, obesity, diabetes, and cancer. This was the MAHA agenda item with the broadest public support. **Fluoride action.** The FDA announced it may take action against unapproved prescription fluoride supplements for young children, with Makary stating fluoride could harm gut bacteria. This aligned with [[RFK Jr.]]'s long-standing anti-fluoride position. **Hepatitis B vaccine changes.** Under Kennedy's direction, an advisory panel was fired and replaced with new members who changed the recommendation for hepatitis B vaccines for newborns — one of the most concrete vaccine-policy rollbacks. ### The Procedural Pattern A consistent feature of Makary's tenure: major policy changes were announced through medical journal op-eds, TV interviews, and social media posts rather than through formal FDA rulemaking. STAT News documented that the FDA under Makary operated through "lots of media announcements but not much rulemaking" — a pattern that generated headlines without the legal durability of formal regulation. This mirrors the broader Trump-administration pattern of governance-by-announcement. ## The Ouster (May 2026) As of May 8, 2026, Trump has reportedly signed off on firing Makary. The reasons illuminate the structural position Makary occupied — caught between the MAHA movement's demands and Trump's personal priorities: **Flavored vapes.** Trump had pledged during the 2024 campaign to protect flavored e-cigarettes. Makary moved too slowly on approvals, and Trump reportedly rebuked him over the weekend of May 3–4 for not fast-tracking flavored vape products. The irony: MAHA's stated mission is to "make America healthy again," but the President wants his FDA chief to approve addictive nicotine delivery devices faster. The FDA under Makary had already authorized [[Juul]]'s tobacco and menthol products in July 2025, four months after his son's firm [[1789 Capital]] bought a stake. **Abortion pill (mifepristone).** Makary slow-walked a safety study on the abortion pill, frustrating anti-abortion Republicans. This put him crosswise with a different wing of the Trump coalition — the Christian nationalist faction that wants the FDA to restrict reproductive rights. **General management friction.** Pharmaceutical companies were unhappy with Makary's drug-approval process management. Administration officials questioned his handling of the FDA's sprawling portfolio. The ouster pattern is instructive: Makary was brought in as the "credible" face for MAHA-adjacent FDA policy, but the actual demands of the Trump coalition — vape approvals for the libertarian/populist wing, abortion restrictions for the Christian nationalist wing, fast drug approvals for the pharma-donor wing — were in structural tension with each other and with the MAHA health-purity agenda. ## The Analytical Frame Makary is a case study in **[[Reputation Mining]]**. His Johns Hopkins pedigree, surgical credentials, and mainstream publications provided institutional legitimacy for a political project — the MAHA agenda — that includes genuinely evidence-based reforms (food dye restrictions, healthcare pricing transparency) alongside anti-scientific positions (vaccine restriction, fluoride conspiracy, anti-public-health-institution posture). His presence as FDA commissioner signaled that the MAHA agenda was "mainstream medicine" rather than "anti-vax conspiracy" — even as the specific policy actions moved closer to the latter. The fact that he is being fired not for the health-skeptic positions but for failing to be sufficiently loyal on vapes and abortion underscores a structural truth about the second Trump administration: policy positions are less important than personal loyalty to the President's immediate political needs. ## See Also - [[MAHA]] — The ideology he implemented at the FDA - [[Anti-Vax Movement]] — The broader movement MAHA partially launders - [[American Enterprise Institute]] — Makary's think-tank home; the institutional on-ramp - [[Second Trump Administration]] — The administration that appointed and is now firing him - [[Project 2025]] — The broader administrative-state restructuring that includes FDA transformation